|
1.
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
2.
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kim ES, Hirsh V, Mok T, et al: Gefitinib
versus docetaxel in previously treated non-small-cell lung cancer
(INTEREST): a randomised phase III trial. Lancet. 372:1809–1818.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Mok TS, Wu Y, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Maheswaran S, Sequist LV, Nagrath S, et
al: Detection of mutations in EGFR in circulating lung-cancer
cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Molina R, Auge JM, Escudero JM, et al:
Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in
patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and
NSE. Tumour Biol. 29:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Okada M, Nishio W, Sakamoto T, et al:
Prognostic significance of perioperative serum carcinoembryonic
antigen in non-small cell lung cancer: analysis of 1,000
consecutive resections for clinical stage I disease. Ann Thorac
Surg. 78:216–221. 2004. View Article : Google Scholar
|
|
8.
|
Pujol JL, Boher JM, Grenier J and Quantin
X: CYFRA 21-1, neuron specific enolase and prognosis of non-small
cell lung cancer: prospective study in 621 patients. Lung Cancer.
31:221–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Holdenrieder S, von Pawel J, Dankelmann E,
et al: Nucleosomes and CYFRA 21-1 indicate tumor response after one
cycle of chemotherapy in recurrent non-small cell lung cancer. Lung
Cancer. 63:128–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ardizzoni A, Cafferata MA, Tiseo M, et al:
Decline in serum carcinoembryonic antigen and cytokeratin 19
fragment during chemotherapy predicts objective response and
survival in patients with advanced non-small cell lung cancer.
Cancer. 107:2842–2849. 2006. View Article : Google Scholar
|
|
11.
|
Okamoto T, Nakamura T, Ikeda J, et al:
Serum carcinoembryonic antigen as a predictive marker for
sensitivity to gefitinib in advanced non-small cell lung cancer.
Eur J Cancer. 41:1286–1290. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Barlsi F, Tchouhadjian C, Doddoli C, Torre
JP, Astoul P and Kleisbauer JP: CYFRA 21-1 level predicts survival
in non-small cell lung cancer patients receiving gefitinib as
third-line therapy. Br J Cancer. 92:13–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Chiu C, Shih Y, Tsai C, Liou J, Chen Y and
Perng R: Serum tumor markers as predictors for survival in advanced
non-small cell lung cancer patients treated with gefitinib. Lung
Cancer. 57:213–221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Travis WD, Colby TV, Corrin B, Shimosato Y
and Brambilla E: Histological Typing of Lung and Pleural Tumours.
3rd edition. Springer-Verlag; Berlin: 1999, View Article : Google Scholar
|
|
15.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
16.
|
Han S, Kim T, Hwang PG, et al: Predictive
and prognostic impact of epidermal growth factor receptor mutation
in non-small-cell lung cancer patients treated with gefitinib. J
Clin Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Gold P and Freedman SO: Demonstration of
tumor-specific antigens in human colonic carcinomata by
immunological tolerance and absorption techniques. J Exp Med.
121:439–462. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Fujishima T, Honda Y, Shijubo N, Takahashi
H and Abe S: Increased carcinoembryonic antigen concentrations in
sera and bronchoalveolar lavage fluids of patients with pulmonary
alveolar proteinosis. Respiration. 62:317–321. 1995. View Article : Google Scholar
|
|
19.
|
Rule AH, Straus E, Vandevoorde J and
Janowitz HD: Tumor-associated (CEA-reacting) antigen in patients
with inflammatory bowel disease. N Engl J Med. 287:24–26. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Okada M, Nishio W, Sakamoto T, et al:
Effect of histologic type and smoking status on interpretation of
serum carcinoembryonic antigen value in non-small cell lung
carcinoma. Ann Thorac Surg. 78:1004–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Matsuoka K, Sumitomo S, Nakashima N,
Nakajima D and Misaki N: Prognostic value of carcinoembryonic
antigen and CYFRA21-1 in patients with pathological stage I
non-small cell lung cancer. Eur J Cardiothorac Surg. 32:435–439.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Shoji F, Yoshino I, Yano T, et al: Serum
carcinoembryonic antigen level is associated with epidermal growth
factor receptor mutations in recurrent lung adenocarcinomas.
Cancer. 110:2793–2798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Benchimol S, Fuks A, Jothy S, Beauchemin
N, Shirota K and Stanners CP: Carcinoembryonic antigen, a human
tumor marker, functions as an intercellular adhesion molecule.
Cell. 57:327–334. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hammarström S: The carcinoembryonic
antigen (CEA) family: structures, suggested functions and
expression in normal and malignant tissues. Semin Cancer Biol.
9:67–81. 1999.PubMed/NCBI
|
|
25.
|
Screaton RA, Penn LZ and Stanners CP:
Carcinoembryonic antigen, a human tumor marker, cooperates with Myc
and Bcl-2 in cellular transformation. J Cell Biol. 137:939–952.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ordoez C, Screaton RA, Ilantzis C and
Stanners CP: Human carcinoembryonic antigen functions as a general
inhibitor of anoikis. Cancer Res. 60:3419–3424. 2000.PubMed/NCBI
|
|
27.
|
Stieber P, Bodenmller H, Banauch D, et al:
Cytokeratin 19 fragments: a new marker for non-small cell lung
cancer. Clin Biochem. 26:301–304. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Nisman B, Lafair J, Heching N, et al:
Evaluation of tissue polypeptide-specific antigen, CYFRA 21-1, and
carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the
combined use of cytokeratin markers give any additional
information? Cancer. 82:1850–1859. 1998. View Article : Google Scholar
|
|
29.
|
Barlsi F, Gimenez C, Torre J, et al:
Prognostic value of combination of CYFRA 21-1, CEA and NSE in
patients with advanced non-small cell lung cancer. Respir Med.
98:357–362. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Pujol JL, Molinier O, Ebert W, et al:
CYFRA 21-1 is a prognostic determinant in non-small-cell lung
cancer: results of a meta-analysis in 2063 patients. Br J Cancer.
90:2097–2105. 2004.PubMed/NCBI
|
|
31.
|
Kao CH, Hsieh JF, Ho YJ, Tsai SC and Lee
JK: Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers.
Anticancer Res. 19:4545–4546. 1999.PubMed/NCBI
|
|
32.
|
Molina R, Filella X, Aug JM, et al: Tumor
markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with
non-small cell lung cancer as an aid in histological diagnosis and
prognosis. Comparison with the main clinical and pathological
prognostic factors. Tumour Biol. 24:209–218. 2003. View Article : Google Scholar
|
|
33.
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
